CRISPR/Cas9 – Talk Bio

Actionable Insights Powered by AI

Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches

6 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, commercial, CRISPR/Cas9, gene therapy, Infusion procedures, launches, United States Food and Drug Administration

CASGEVY, Vertex Pharmaceuticals, gene therapy, sickle cell disease, beta thalassemia, CRISPR/Cas9, FDA approval, commercial patient infusions, 2025 launches.